Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial

被引：0

作者：

Ettinger, D. S. ^{[1
]}

Jotte, R. ^{[2
]}

Lorigan, P. ^{[3
]}

Gupta, V. ^{[4
]}

Garbo, L. ^{[5
]}

Spigel, D. ^{[6
]}

Dudek, A. Z. ^{[7
]}

Salgia, R. ^{[8
]}

McNally, R. ^{[9
]}

Renschler, M. ^{[10
]}

机构：

[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[2] Rocky Mt Canc Ctr US Oncol, Denver, CO USA

[3] Christie Hosp, NHS Fdn Trust, Manchester, Lancs, England

[4] St Joseph Oncol US Oncol, St Joseph, MO USA

[5] New York Oncol Hematol US Oncol, Albany, NY USA

[6] Sarah Cannon Canc Ctr, Nashville, TN USA

[7] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA

[8] Univ Chicago, Chicago, IL 60637 USA

[9] Celgene Corp, Biostat, Summit, NJ USA

[10] Celgene Corp, Clin Dev, Summit, NJ USA

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1359-6349(09)71834-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：541 / 541

页数：1

共 50 条

[1] Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: updated results of a phase 2 trial
Ettinger, David S.
Jotte, Robert M.
Paul, Lorigan
Gupta, Vicram
Garbo, Lawrence
Alemany, Carlos
Spigel, David R.
Dudek, Arkadiusz Z.
Salgia, Ravi
McNally, Richard
Renschler, Markus
Oliver, Jennifer W.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S398 - S399
[2] Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update
Ettinger, D. S.
Jotte, R.
Lorigan, P.
Gupta, V.
Garbo, L.
Conkling, P.
Spigel, D.
McNally, R.
Renschler, M.
Oliver, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[3] Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy
Jotte, R.
Conkling, P.
Reynolds, C.
Klein, L.
Fitzgibbons, J. F.
McNally, R.
Renschler, M.
Oliver, J. W.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[4] Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial
Jotte, R.
Conkling, P. R.
Reynolds, C.
Shah, C.
Galsky, M.
Klein, L.
Fitzgibbons, J. F.
McNally, R.
Oliver, J. W.
Renschler, M.
EJC SUPPLEMENTS, 2009, 7 (02): : 540 - 541
[5] A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy
Ettinger, D. S.
Jotte, R. M.
Gupta, V.
Allen, A. R.
Oliver, J. W.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[6] Second-line amrubicin (AMR) vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum based chemotherapy: updated results of a randomized phase 2 trial
Jotte, Robert M.
Conkling, Paul
Reynolds, Craig
Shah, Chirag
Galsky, Matthew D.
Klein, Leonard
Fitzgibbons, James F.
McNally, Richard
Renschler, Markus
Oliver, Jennifer W.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S399 - S399
[7] A randomized phase 2 trial of amrubicin compared to topotecan as second-line treatments in extensive disease small cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
Jotte, R. M.
Reynolds, C. H.
Conkling, P.
Oliver, J. W.
Allen, A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[8] AMRUBICIN (AMR) VS TOPOTECAN AS SECOND-LINE TREATMENT OF EXTENSIVE-DISEASE SMALL CELL LUNG CANCER (SCLC) SENSITIVE TO PLATINUM-BASED FIRST-LINE CHEMOTHERAPY: A RANDOMIZED PHASE 2 TRIAL
Jotte, R. M.
Reynolds, C.
Conkling, P.
Jungnelius, U.
Oliver, J.
ANNALS OF ONCOLOGY, 2008, 19 : 116 - 116
[9] A phase III study of rovalpituzumab tesirine maintenance therapy following first-line platinum-based chemotherapy in patients with extensive disease small cell lung cancer (ED SCLC).
Komarnitsky, Philip B.
Lee, Ho-Jin
Shah, Manan
Wong, Shekman
Gauthier, Sanja
Dziubinski, Juliann
Osbaugh, Stacy
Zhang, Fan
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[10] IPILIMUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT IN EXTENSIVE DISEASE-SMALL CELL LUNG CANCER (ED-SCLC): RESULTS FROM A PHASE 2 TRIAL
Reck, Martin
Bondarenko, Igor
Luft, Alexander
Serwatowski, Piotr
Barlesi, Fabrice
Chacko, Raju
Sebastian, Martin
Siegel, Jonathan
Cuillerot, Jean-Marie
Lynch, Thomas
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S310 - S311

← 1 2 3 4 5 →